Novasep plans to invest €10 million to build a fully integrated Antibody Drug Conjugate (ADC) facility at its Le Mans site in France. The new facility will complement its current ADC offering with full bio-conjugation services.
 
The facility, to be built in 2Q16, will provide contract manufacturing in batch sizes from a few milligrams to 600g to ADC drug developers during clinical trial and commercial development phases.
 
“Combining chemistry and biology is not a given. Novasep is one of the few CMOs able to produce both commercial scale ADCs payloads and monoclonal antibodies,” said Thierry Van Nieuwenhove, president of Novasep’s Synthesis BU. “Customers are now searching for a simplified supply chain to produce their ADC and other bio-conjugate drug substances. By integrating our R&D, analytical and manufacturing services within a single unit, we can give customers flexibility, assurance of supply and continuity in supply chains.”
 
According to the company, the new ADC facility will be capable of producing ADCs in full compliance with the highest standards in quality and safety.